{"ticker": {"uuid": "9a763191-351f-4013-bf5e-0101b9689c51", "symbol": "VTVT", "name": "vTv Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOdXc0dmt1MlM4b3Rjdm1SdVE4WFlodHdYS05SQzZJZTZlX1ltQ1EyZzAtWk4tLXdzWnBtd3FjT1hSWUFPZjBiLXIwOHB2eGlncWdqU3FPY1ZJcC0za1ZlckljU3BYVkdWOS1WUE9yZDBuOEY0Y0JjZFFpZVdSV2VsRkI4bkl4YzFGa29ob0pUejRmTzVsYnF0OHN6SmNkaVZBWVhiRGtOdFFjN1F5eF9SM25aYk5XMU5xSWg2MWYzNkJObU9jQlZhNXhOUzhqZi1UYVJn?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-16T12:42:05+00:00", "published_display": "16 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds", "summary": "vTv Therapeutics director Dr. Raymond Cheong received a grant of 6,000 non-qualified stock options, exercisable into Class A common stock at $35.08 per share. These options, vesting on June 26, 2027, or the 2027 annual shareholder meeting, are tied to Baker Bros.-affiliated funds", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-557d723d0472.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:11", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) director granted 6,000 stock options at $35.08", "summary": "vTv Therapeutics director Daniel K. Spiegelman was granted 6,000 stock options to purchase Class A Common Stock at $35.08 per share. These options are part of his director compensation, expire in 2036, and will vest on the earlier of June 26, 2027, or the 2027 annual general meet", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-fc6469595287.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Fahed Al-Marzooqi (VTVT) granted 6,000 vTv Therapeutics stock options", "summary": "Fahed Al-Marzooqi, a director at vTv Therapeutics Inc. (VTVT), was granted 6,000 stock options for Class A common stock with an exercise price of $35.08 per share. These options will vest on the earlier of June 26, 2027, or the 2027 annual general meeting, provided he continues h", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-477943ac6d03.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at vTv Therapeutics (VTVT) receives 6,000 stock options grant", "summary": "vTv Therapeutics director Anne M. Phillips was granted options to purchase 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These options are part of her board compensation and will expire on June 26, 2036. The options vest on the earlier of June 26,", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-8fd0a26c8e9b.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant", "summary": "vTv Therapeutics director Srinivas Akkaraju was granted 6,000 stock options with an exercise price of $35.08 per share, expiring in 2036. These options will vest on the earlier of June 26, 2027, or the 2027 annual general meeting, provided Akkaraju continues serving on the board.", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-e5fc4f35f7e0.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VTVT)", "summary": "This article provides financial actuals and estimates for vTv Therapeutics Inc. (NASDAQ: VTVT), covering its stock performance, analyst forecasts, earnings, revenue, and other key financial metrics. It details the company's current stock price, historical highs and lows, market c", "url": "https://www.tradingview.com/symbols/NASDAQ-VTVT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:43", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics, Inc. Class A Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of vTv Therapeutics Inc.'s (VTVT) financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details earnings releases and quarterly/annual reports from 2020 through Q1 2026, allowing users to evaluate the company's f", "url": "https://www.tradingview.com/symbols/NASDAQ-VTVT/documents/", "source_name": "TradingView", "published_at": "2026-06-06T21:09:52", "published_display": "06 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock options, 10-year term: inside vTv Therapeutics grant", "summary": "vTv Therapeutics (Nasdaq: VTVT) announced the grant of 2,500 stock options to a new non-executive employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30, vest over four years, and have a 10-year ter", "url": "https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-announces-inducement-grants-under-nasdaq-listing-rc3nzfpmmfbl.html", "source_name": "Stock Titan", "published_at": "2026-06-06T14:39:12", "published_display": "06 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced it granted 2,500 stock options to a non-executive employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30 per share and will v", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vtv-therapeutics-announces-inducement-grants-200500992.html", "source_name": "Market source", "published_at": "2026-06-02T15:05:00", "published_display": "02 Jun 2026 15:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. (VTVT) Slips 3% as Resistance Holds; Traders Eye Support Test - Price Surge Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQM2RMb2NqWnpxZ1ZYSGRrZ2hVUmxodWNUMnY0em9IVjVMQmh0aTZGY3JzU3c5NS1wUW5PejdTLUQxOFZVbERpb0cwUnpZUXE3aHo4MGhkc2VUS2JacVVsX3pDNk5hV2lvZVFyOVpJbzEzSUN1REZWY2w4WnFhenMtSUwyUlpSZmo0R0JvZ280dW55bjZoQmxZSlJoUXJ2QUpOUm5PM3p2OGpHMmJ6czlfYzQwNjFETVpoc1BfaHBabw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vtv-therapeutics-inc-nasdaq-vtvt-132602087.html", "source_name": "Simply Wall St.", "published_at": "2026-05-17T13:26:02+00:00", "published_display": "17 May 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vtv-therapeutics-vtvt-move-heres-125503455.html", "source_name": "Zacks", "published_at": "2026-05-15T12:55:03+00:00", "published_display": "15 May 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VTV Therapeutics (VTVT) Q1 Profit Swing To US$1.94 EPS Tests Bullish Narratives", "summary": "VTV Therapeutics (VTVT) reported a significant shift in its Q1 2026 financials, moving from quarterly losses to a profit of US$1.94 EPS and US$36.8 million in revenue. This change raises questions about the durability of the new profit profile, especially given forecasts of a 20.", "url": "https://www.sahmcapital.com/news/content/vtv-therapeutics-vtvt-q1-profit-swing-to-us194-eps-tests-bullish-narratives-2026-05-15", "source_name": "Sahm", "published_at": "2026-05-15T01:40:36", "published_display": "15 May 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq \u2013 Company Information and SEC Filing Details", "summary": "vTv Therapeutics Inc. has filed a Form 8-K to announce a significant expansion of its at-the-market (ATM) equity offering program, increasing the aggregate offering price to up to $47,500,000. This move allows the company to raise substantial capital for operations, research, or ", "url": "https://www.minichart.com.sg/2026/05/14/vtv-therapeutics-inc-files-form-8-k-for-class-a-common-stock-on-nasdaq-company-information-and-sec-filing-details/", "source_name": "Minichart", "published_at": "2026-05-14T08:40:01", "published_display": "14 May 2026 08:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts vTv Therapeutics stock price target to $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNYVk4aG91UmV6ZWREYkQ0VW9HNU5oTV9GeXNHTV9TNkRmVlVKU092bm5Gd2RoNW5kZGtpR2tHT0pUSjkwQk1UaS1qdWw5NEdhZFhNNlVxa0JsWWVWWUdpM2RCMjJEZm54S1ViVmZuNE52ckpWTzk4ZGtUTU1XWlU3cGlOWXB5eHhqMDJ2bEtuenNFZTFNX1hVVjVMS29WbWZrTUY0cFhpX0xoZXl1ejVSSDNYQlRkVjFWRnpLeQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash", "summary": "vTv Therapeutics (NASDAQ: VTVT) reported a significant financial turnaround in Q1 2026, achieving a net income of $24.1 million, a substantial improvement from a $6.2 million loss in the prior year. This profit was primarily driven by $36.8 million in licensing revenue, including", "url": "https://www.stocktitan.net/sec-filings/VTVT/10-q-v-tv-therapeutics-inc-quarterly-earnings-report-3f8319fa95c5.html", "source_name": "Stock Titan", "published_at": "2026-05-14T00:39:27", "published_display": "14 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount.", "summary": "vTv Therapeutics Inc. has filed with the U.S. SEC, indicating an increase in the allocation of Class A common shares under its at-the-market offering plan to the full authorized amount. This move signifies the company's intention to fully utilize its equity financing quota.", "url": "https://www.bitget.com/asia/amp/news/detail/12560605411166", "source_name": "Bitget", "published_at": "2026-05-13T22:40:00", "published_display": "13 May 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin", "summary": "vTv Therapeutics has registered an \"at-the-market\" (ATM) offering of up to $47.5 million in Class A common stock through TD Cowen to fund the development of its lead product candidate, cadisegliatin. The proceeds will support general corporate purposes, including manufacturing, c", "url": "https://www.stocktitan.net/sec-filings/VTVT/424b2-v-tv-therapeutics-inc-prospectus-supplement-dbc33f9a242e.html", "source_name": "Stock Titan", "published_at": "2026-05-13T21:40:17", "published_display": "13 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion", "summary": "vTv Therapeutics Inc. (VTVT) has filed an 8-K to announce an expansion of its at-the-market (ATM) stock sales program. The company filed a prospectus supplement to increase the offered Class A common shares to the full amount allowed by the ATM agreement and included a legal opin", "url": "https://www.stocktitan.net/sec-filings/VTVT/8-k-v-tv-therapeutics-inc-reports-material-event-c258bd6c8a7f.html", "source_name": "Stock Titan", "published_at": "2026-05-13T21:40:17", "published_display": "13 May 2026 21:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTv Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/vtv-therapeutics-q1-earnings-snapshot-200653898.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:06:53+00:00", "published_display": "13 May 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] vTv Therapeutics Inc. Reports Material Event", "summary": "vTv Therapeutics Inc. reported a significant turnaround in its first quarter of 2026, driven by a major licensing payment, resulting in $36.8 million in revenue and $24.1 million in net income. The company's cash position of $98.1 million is expected to fund operations through th", "url": "https://www.stocktitan.net/sec-filings/VTVT/8-k-v-tv-therapeutics-inc-reports-material-event-9e48622e09a9.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:40:17", "published_display": "13 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "vTv Therapeutics (Nasdaq: VTVT) announced its first quarter 2026 financial results, highlighting the ongoing progress of its Phase 3 CATT1 trial for cadisegliatin, an investigational treatment for type 1 diabetes. The company expects to complete enrollment in the third quarter of", "url": "https://www.manilatimes.net/2026/05/14/tmt-newswire/globenewswire/vtv-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update/2343342/amp", "source_name": "The Manila Times", "published_at": "2026-05-13T20:40:17", "published_display": "13 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oral type 1 diabetes drug advances: vTv expects cash through Phase 3 data", "summary": "vTv Therapeutics reported a strong Q1 2026 with $36.8 million in revenue and $24.1 million in net income, boosting cash and equivalents to $98.1 million. The company is on track to complete enrollment for its Phase 3 CATT1 trial of cadisegliatin, an oral adjunctive therapy for ty", "url": "https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-reports-first-quarter-2026-financial-results-and-0r5nfhls5qqq.html", "source_name": "Stock Titan", "published_at": "2026-05-13T19:40:17", "published_display": "13 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Two new vTv hires get 39,500 stock options at $32 a share", "summary": "vTv Therapeutics granted 39,500 stock options to two new non-executive employees as a material inducement for employment. The options have a weighted average exercise price of $32.00 per share, vest over four years, and have a 10-year term. This aligns with the company's 2026 Ind", "url": "https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-announces-inducement-grants-under-nasdaq-listing-wjh52stz8qo8.html", "source_name": "Stock Titan", "published_at": "2026-05-08T15:12:10", "published_display": "08 May 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics to Participate in Upcoming May Investor Conferences", "summary": "vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced its participation in two investor conferences in May: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Alliance Global Partners Healthcare Company Showcase. The company will discuss its ", "url": "https://www.manilatimes.net/2026/05/07/tmt-newswire/globenewswire/vtv-therapeutics-to-participate-in-upcoming-may-investor-conferences/2338365/amp", "source_name": "The Manila Times", "published_at": "2026-05-07T12:10:00", "published_display": "07 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (NASDAQ: VTVT) details 2026 virtual annual meeting, board and pay", "summary": "vTv Therapeutics is holding its 2026 annual virtual-only meeting on June 10, 2026, where stockholders will vote on electing seven directors and ratifying Ernst & Young LLP as the independent auditor. The proxy statement details the company's governance structure, board compositio", "url": "https://www.stocktitan.net/sec-filings/VTVT/def-14a-v-tv-therapeutics-inc-definitive-proxy-statement-7520ba3e62b6.html", "source_name": "Stock Titan", "published_at": "2026-04-29T04:39:27", "published_display": "29 Apr 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?", "summary": "Wall Street analysts project a 39.9% upside for vTv Therapeutics (VTVT), with a mean price target of $53.33, despite the stock gaining 5.9% in the past four weeks. While investors often rely on such targets, the article cautions against making investment decisions solely based on", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-39-135502463.html", "source_name": "Market source", "published_at": "2026-04-20T04:09:26", "published_display": "20 Apr 2026 04:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium entities, Israel A. Englander disclose stakes in vTv Therapeutics (VTVT)", "summary": "Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G/A, disclosing their beneficial ownership in vTv Therapeutics (VTVT). Integrated Core Strategies (US) LLC holds a 5.0% stake,", "url": "https://www.stocktitan.net/sec-filings/VTVT/schedule-13g-a-v-tv-therapeutics-inc-amended-passive-investment-discl-50efe7d740e1.html", "source_name": "Stock Titan", "published_at": "2026-04-16T21:38:54", "published_display": "16 Apr 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of \"Moderate Buy\" from Analysts", "summary": "vTv Therapeutics Inc. (NASDAQ:VTVT) has received a consensus \"Moderate Buy\" rating from analysts, with an average 12-month target price of $53.00. Institutional ownership in the company has increased recently, with holdings now at 17.51%. The biotechnology company recently report", "url": "https://www.marketbeat.com/instant-alerts/vtv-therapeutics-inc-nasdaqvtvt-receives-average-rating-of-moderate-buy-from-analysts-2026-04-15/", "source_name": "MarketBeat", "published_at": "2026-04-16T07:40:24", "published_display": "16 Apr 2026 07:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think vTv Therapeutics (NASDAQ:VTVT) Can Easily Afford To Drive Business Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "vTv Therapeutics to Participate in the 38th Annual ROTH Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQcEF1Y29TX1BCV0Q2VC12NXFYRmd2V05GdkRhYi1IZW9EQlRlTnFuV3NnNVdfc2pDbG80YzlNemlZaV9MWEl3SVEzZ0RrRTVnZkxySm9TQzFxTFRmY0NacjRIYmtMcjRXSWlDME9MU0F6UjdKeVRQX2FwcDN0dnhnTU1DOTlMalpadHB3QUFLcG5YU3pTaHppR09HZEJLa1V5OS1BeU9DTlFpdHUwdU1kaWUwWml1alZPbUd5LVR3NElHLUdyZmdsUmRJbnlKbURpdXlCYQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQb0h2anhxeHVJa0EyMGcxTDhMal9lZDR4dzY0dVM2ZGRtam9hYkI1T0lGQ2FfbERGU1lXNDZORWZLMzk5cGxQWUpoMFp4eXZxR3J1dmNxaUZIbzJvSzVmSXRaS3dLSXp4QWFWZG9WdklmMDlsVGdGOUpXVTJnbHFPNy04dmVyd0g3UlE?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOMTVrbmMtTmVFemZKWEJJelA4c0ZXZVdwSG52R0JKbUkydXBobGRxSUFKaEl3ekNEUXZZVWt4UDllUWZrdG55ZGc3QlNfdUx4bURyY2dvbGpjRm5iek0zeWNOUExHMWRMZFltWXp1WEZCZVgxQ1o3TzdoWEVERUNKamlqd195SVpTWDlMajBZa25sSkw2a3pMcE5EMXhRWmdLc2c3eHJET0ViQ0sxZmhZVUhWM2ZRUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VTVT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5DdE1oVWZzdVltZFRZRktld0liWlF3Z0hXaXVoX1N1b3VxS09LSTMzMUxHTEJ3VF81b2pjS1FxV2ZSbTlpdGVKcF9qV0hBV2NhZ2lnOHdkbGF6ZGM1TFcySWVLUThZTXlR?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T17:38:23+00:00", "published_display": "09 Jul 2025 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vtv Therapeutics (VTVT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBUTkJjeXhQaFN3RVNGV3pMWjFuWEgwUUgwWGFobDluM1YyS2hOMVJ4VnNsLThsNUZTem1DSzQ1dTB3V2VicHhEQjZnWjBmdjRyV2VF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:41:16+00:00", "published_display": "25 Apr 2025 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) Stock Forecast and Price Target 2026 $VTVT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE10MV90R19jRGRKSzNCSHhZNmZSekhYT3NYTXo4bUdnN19FMFNUREx2UGg4b2RHelJNc0tlMUNYcGhFVnhrVnQtYkQtUXlDQXI0UzVMMUhPUF9Ha1BnYlBCS0plZ1dOQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-14T23:41:21+00:00", "published_display": "14 May 2024 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTVT: vTv Therapeutics Inc - Ordinary Shares - Class A Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE5DUl9aWWFiOFhlejRjNVFVbmxGZmc2T3dsWmIwRWlxWDhocjhpSWFWZ2VGYzM0czc5azREVDZfZ29BSEdrOS1FREhR?oc=5", "source_name": "Stocktwits", "published_at": "2016-09-29T14:36:42+00:00", "published_display": "29 Sep 2016 14:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics - VTVT - Stock Price Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTFBUald1YVNPSmFJNzNtQmlrVVZvZHFxa3FvU2NEX2liOGFNUGYzOW5oX3dKc0RHUUZ4V3hzNG5PSnF3eXhTQkRmdlIyRWZLeWM?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-04-28T22:07:54+00:00", "published_display": "28 Apr 2016 22:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOdXc0dmt1MlM4b3Rjdm1SdVE4WFlodHdYS05SQzZJZTZlX1ltQ1EyZzAtWk4tLXdzWnBtd3FjT1hSWUFPZjBiLXIwOHB2eGlncWdqU3FPY1ZJcC0za1ZlckljU3BYVkdWOS1WUE9yZDBuOEY0Y0JjZFFpZVdSV2VsRkI4bkl4YzFGa29ob0pUejRmTzVsYnF0OHN6SmNkaVZBWVhiRGtOdFFjN1F5eF9SM25aYk5XMU5xSWg2MWYzNkJObU9jQlZhNXhOUzhqZi1UYVJn?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-16T12:42:05+00:00", "published_display": "16 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds", "summary": "vTv Therapeutics director Dr. Raymond Cheong received a grant of 6,000 non-qualified stock options, exercisable into Class A common stock at $35.08 per share. These options, vesting on June 26, 2027, or the 2027 annual shareholder meeting, are tied to Baker Bros.-affiliated funds", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-557d723d0472.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:11", "published_display": "29 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) director granted 6,000 stock options at $35.08", "summary": "vTv Therapeutics director Daniel K. Spiegelman was granted 6,000 stock options to purchase Class A Common Stock at $35.08 per share. These options are part of his director compensation, expire in 2036, and will vest on the earlier of June 26, 2027, or the 2027 annual general meet", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-fc6469595287.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Fahed Al-Marzooqi (VTVT) granted 6,000 vTv Therapeutics stock options", "summary": "Fahed Al-Marzooqi, a director at vTv Therapeutics Inc. (VTVT), was granted 6,000 stock options for Class A common stock with an exercise price of $35.08 per share. These options will vest on the earlier of June 26, 2027, or the 2027 annual general meeting, provided he continues h", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-477943ac6d03.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at vTv Therapeutics (VTVT) receives 6,000 stock options grant", "summary": "vTv Therapeutics director Anne M. Phillips was granted options to purchase 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These options are part of her board compensation and will expire on June 26, 2036. The options vest on the earlier of June 26,", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-8fd0a26c8e9b.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at vTv Therapeutics (VTVT) awarded 6,000 stock options grant", "summary": "vTv Therapeutics director Srinivas Akkaraju was granted 6,000 stock options with an exercise price of $35.08 per share, expiring in 2036. These options will vest on the earlier of June 26, 2027, or the 2027 annual general meeting, provided Akkaraju continues serving on the board.", "url": "https://www.stocktitan.net/sec-filings/VTVT/form-4-v-tv-therapeutics-inc-insider-trading-activity-e5fc4f35f7e0.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:11", "published_display": "29 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VTVT)", "summary": "This article provides financial actuals and estimates for vTv Therapeutics Inc. (NASDAQ: VTVT), covering its stock performance, analyst forecasts, earnings, revenue, and other key financial metrics. It details the company's current stock price, historical highs and lows, market c", "url": "https://www.tradingview.com/symbols/NASDAQ-VTVT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:10:43", "published_display": "26 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics, Inc. Class A Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of vTv Therapeutics Inc.'s (VTVT) financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details earnings releases and quarterly/annual reports from 2020 through Q1 2026, allowing users to evaluate the company's f", "url": "https://www.tradingview.com/symbols/NASDAQ-VTVT/documents/", "source_name": "TradingView", "published_at": "2026-06-06T21:09:52", "published_display": "06 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock options, 10-year term: inside vTv Therapeutics grant", "summary": "vTv Therapeutics (Nasdaq: VTVT) announced the grant of 2,500 stock options to a new non-executive employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30, vest over four years, and have a 10-year ter", "url": "https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-announces-inducement-grants-under-nasdaq-listing-rc3nzfpmmfbl.html", "source_name": "Stock Titan", "published_at": "2026-06-06T14:39:12", "published_display": "06 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "summary": "vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced it granted 2,500 stock options to a non-executive employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30 per share and will v", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vtv-therapeutics-announces-inducement-grants-200500992.html", "source_name": "Market source", "published_at": "2026-06-02T15:05:00", "published_display": "02 Jun 2026 15:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. (VTVT) Slips 3% as Resistance Holds; Traders Eye Support Test - Price Surge Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQM2RMb2NqWnpxZ1ZYSGRrZ2hVUmxodWNUMnY0em9IVjVMQmh0aTZGY3JzU3c5NS1wUW5PejdTLUQxOFZVbERpb0cwUnpZUXE3aHo4MGhkc2VUS2JacVVsX3pDNk5hV2lvZVFyOVpJbzEzSUN1REZWY2w4WnFhenMtSUwyUlpSZmo0R0JvZ280dW55bjZoQmxZSlJoUXJ2QUpOUm5PM3p2OGpHMmJ6czlfYzQwNjFETVpoc1BfaHBabw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vtv-therapeutics-inc-nasdaq-vtvt-132602087.html", "source_name": "Simply Wall St.", "published_at": "2026-05-17T13:26:02+00:00", "published_display": "17 May 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/vtv-therapeutics-vtvt-move-heres-125503455.html", "source_name": "Zacks", "published_at": "2026-05-15T12:55:03+00:00", "published_display": "15 May 2026 12:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTV Therapeutics (VTVT) Q1 Profit Swing To US$1.94 EPS Tests Bullish Narratives", "summary": "VTV Therapeutics (VTVT) reported a significant shift in its Q1 2026 financials, moving from quarterly losses to a profit of US$1.94 EPS and US$36.8 million in revenue. This change raises questions about the durability of the new profit profile, especially given forecasts of a 20.", "url": "https://www.sahmcapital.com/news/content/vtv-therapeutics-vtvt-q1-profit-swing-to-us194-eps-tests-bullish-narratives-2026-05-15", "source_name": "Sahm", "published_at": "2026-05-15T01:40:36", "published_display": "15 May 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq \u2013 Company Information and SEC Filing Details", "summary": "vTv Therapeutics Inc. has filed a Form 8-K to announce a significant expansion of its at-the-market (ATM) equity offering program, increasing the aggregate offering price to up to $47,500,000. This move allows the company to raise substantial capital for operations, research, or ", "url": "https://www.minichart.com.sg/2026/05/14/vtv-therapeutics-inc-files-form-8-k-for-class-a-common-stock-on-nasdaq-company-information-and-sec-filing-details/", "source_name": "Minichart", "published_at": "2026-05-14T08:40:01", "published_display": "14 May 2026 08:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright cuts vTv Therapeutics stock price target to $45", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNYVk4aG91UmV6ZWREYkQ0VW9HNU5oTV9GeXNHTV9TNkRmVlVKU092bm5Gd2RoNW5kZGtpR2tHT0pUSjkwQk1UaS1qdWw5NEdhZFhNNlVxa0JsWWVWWUdpM2RCMjJEZm54S1ViVmZuNE52ckpWTzk4ZGtUTU1XWlU3cGlOWXB5eHhqMDJ2bEtuenNFZTFNX1hVVjVMS29WbWZrTUY0cFhpX0xoZXl1ejVSSDNYQlRkVjFWRnpLeQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash", "summary": "vTv Therapeutics (NASDAQ: VTVT) reported a significant financial turnaround in Q1 2026, achieving a net income of $24.1 million, a substantial improvement from a $6.2 million loss in the prior year. This profit was primarily driven by $36.8 million in licensing revenue, including", "url": "https://www.stocktitan.net/sec-filings/VTVT/10-q-v-tv-therapeutics-inc-quarterly-earnings-report-3f8319fa95c5.html", "source_name": "Stock Titan", "published_at": "2026-05-14T00:39:27", "published_display": "14 May 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount.", "summary": "vTv Therapeutics Inc. has filed with the U.S. SEC, indicating an increase in the allocation of Class A common shares under its at-the-market offering plan to the full authorized amount. This move signifies the company's intention to fully utilize its equity financing quota.", "url": "https://www.bitget.com/asia/amp/news/detail/12560605411166", "source_name": "Bitget", "published_at": "2026-05-13T22:40:00", "published_display": "13 May 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin", "summary": "vTv Therapeutics has registered an \"at-the-market\" (ATM) offering of up to $47.5 million in Class A common stock through TD Cowen to fund the development of its lead product candidate, cadisegliatin. The proceeds will support general corporate purposes, including manufacturing, c", "url": "https://www.stocktitan.net/sec-filings/VTVT/424b2-v-tv-therapeutics-inc-prospectus-supplement-dbc33f9a242e.html", "source_name": "Stock Titan", "published_at": "2026-05-13T21:40:17", "published_display": "13 May 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion", "summary": "vTv Therapeutics Inc. (VTVT) has filed an 8-K to announce an expansion of its at-the-market (ATM) stock sales program. The company filed a prospectus supplement to increase the offered Class A common shares to the full amount allowed by the ATM agreement and included a legal opin", "url": "https://www.stocktitan.net/sec-filings/VTVT/8-k-v-tv-therapeutics-inc-reports-material-event-c258bd6c8a7f.html", "source_name": "Stock Titan", "published_at": "2026-05-13T21:40:17", "published_display": "13 May 2026 21:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTv Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/vtv-therapeutics-q1-earnings-snapshot-200653898.html", "source_name": "Associated Press", "published_at": "2026-05-13T20:06:53+00:00", "published_display": "13 May 2026 20:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] vTv Therapeutics Inc. Reports Material Event", "summary": "vTv Therapeutics Inc. reported a significant turnaround in its first quarter of 2026, driven by a major licensing payment, resulting in $36.8 million in revenue and $24.1 million in net income. The company's cash position of $98.1 million is expected to fund operations through th", "url": "https://www.stocktitan.net/sec-filings/VTVT/8-k-v-tv-therapeutics-inc-reports-material-event-9e48622e09a9.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:40:17", "published_display": "13 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "vTv Therapeutics (Nasdaq: VTVT) announced its first quarter 2026 financial results, highlighting the ongoing progress of its Phase 3 CATT1 trial for cadisegliatin, an investigational treatment for type 1 diabetes. The company expects to complete enrollment in the third quarter of", "url": "https://www.manilatimes.net/2026/05/14/tmt-newswire/globenewswire/vtv-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update/2343342/amp", "source_name": "The Manila Times", "published_at": "2026-05-13T20:40:17", "published_display": "13 May 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oral type 1 diabetes drug advances: vTv expects cash through Phase 3 data", "summary": "vTv Therapeutics reported a strong Q1 2026 with $36.8 million in revenue and $24.1 million in net income, boosting cash and equivalents to $98.1 million. The company is on track to complete enrollment for its Phase 3 CATT1 trial of cadisegliatin, an oral adjunctive therapy for ty", "url": "https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-reports-first-quarter-2026-financial-results-and-0r5nfhls5qqq.html", "source_name": "Stock Titan", "published_at": "2026-05-13T19:40:17", "published_display": "13 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new vTv hires get 39,500 stock options at $32 a share", "summary": "vTv Therapeutics granted 39,500 stock options to two new non-executive employees as a material inducement for employment. The options have a weighted average exercise price of $32.00 per share, vest over four years, and have a 10-year term. This aligns with the company's 2026 Ind", "url": "https://www.stocktitan.net/news/VTVT/v-tv-therapeutics-announces-inducement-grants-under-nasdaq-listing-wjh52stz8qo8.html", "source_name": "Stock Titan", "published_at": "2026-05-08T15:12:10", "published_display": "08 May 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics to Participate in Upcoming May Investor Conferences", "summary": "vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced its participation in two investor conferences in May: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Alliance Global Partners Healthcare Company Showcase. The company will discuss its ", "url": "https://www.manilatimes.net/2026/05/07/tmt-newswire/globenewswire/vtv-therapeutics-to-participate-in-upcoming-may-investor-conferences/2338365/amp", "source_name": "The Manila Times", "published_at": "2026-05-07T12:10:00", "published_display": "07 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (NASDAQ: VTVT) details 2026 virtual annual meeting, board and pay", "summary": "vTv Therapeutics is holding its 2026 annual virtual-only meeting on June 10, 2026, where stockholders will vote on electing seven directors and ratifying Ernst & Young LLP as the independent auditor. The proxy statement details the company's governance structure, board compositio", "url": "https://www.stocktitan.net/sec-filings/VTVT/def-14a-v-tv-therapeutics-inc-definitive-proxy-statement-7520ba3e62b6.html", "source_name": "Stock Titan", "published_at": "2026-04-29T04:39:27", "published_display": "29 Apr 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?", "summary": "Wall Street analysts project a 39.9% upside for vTv Therapeutics (VTVT), with a mean price target of $53.33, despite the stock gaining 5.9% in the past four weeks. While investors often rely on such targets, the article cautions against making investment decisions solely based on", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-39-135502463.html", "source_name": "Market source", "published_at": "2026-04-20T04:09:26", "published_display": "20 Apr 2026 04:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium entities, Israel A. Englander disclose stakes in vTv Therapeutics (VTVT)", "summary": "Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G/A, disclosing their beneficial ownership in vTv Therapeutics (VTVT). Integrated Core Strategies (US) LLC holds a 5.0% stake,", "url": "https://www.stocktitan.net/sec-filings/VTVT/schedule-13g-a-v-tv-therapeutics-inc-amended-passive-investment-discl-50efe7d740e1.html", "source_name": "Stock Titan", "published_at": "2026-04-16T21:38:54", "published_display": "16 Apr 2026 21:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of \"Moderate Buy\" from Analysts", "summary": "vTv Therapeutics Inc. (NASDAQ:VTVT) has received a consensus \"Moderate Buy\" rating from analysts, with an average 12-month target price of $53.00. Institutional ownership in the company has increased recently, with holdings now at 17.51%. The biotechnology company recently report", "url": "https://www.marketbeat.com/instant-alerts/vtv-therapeutics-inc-nasdaqvtvt-receives-average-rating-of-moderate-buy-from-analysts-2026-04-15/", "source_name": "MarketBeat", "published_at": "2026-04-16T07:40:24", "published_display": "16 Apr 2026 07:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think vTv Therapeutics (NASDAQ:VTVT) Can Easily Afford To Drive Business Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics to Participate in the 38th Annual ROTH Conference", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQcEF1Y29TX1BCV0Q2VC12NXFYRmd2V05GdkRhYi1IZW9EQlRlTnFuV3NnNVdfc2pDbG80YzlNemlZaV9MWEl3SVEzZ0RrRTVnZkxySm9TQzFxTFRmY0NacjRIYmtMcjRXSWlDME9MU0F6UjdKeVRQX2FwcDN0dnhnTU1DOTlMalpadHB3QUFLcG5YU3pTaHppR09HZEJLa1V5OS1BeU9DTlFpdHUwdU1kaWUwWml1alZPbUd5LVR3NElHLUdyZmdsUmRJbnlKbURpdXlCYQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQb0h2anhxeHVJa0EyMGcxTDhMal9lZDR4dzY0dVM2ZGRtam9hYkI1T0lGQ2FfbERGU1lXNDZORWZLMzk5cGxQWUpoMFp4eXZxR3J1dmNxaUZIbzJvSzVmSXRaS3dLSXp4QWFWZG9WdklmMDlsVGdGOUpXVTJnbHFPNy04dmVyd0g3UlE?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOMTVrbmMtTmVFemZKWEJJelA4c0ZXZVdwSG52R0JKbUkydXBobGRxSUFKaEl3ekNEUXZZVWt4UDllUWZrdG55ZGc3QlNfdUx4bURyY2dvbGpjRm5iek0zeWNOUExHMWRMZFltWXp1WEZCZVgxQ1o3TzdoWEVERUNKamlqd195SVpTWDlMajBZa25sSkw2a3pMcE5EMXhRWmdLc2c3eHJET0ViQ0sxZmhZVUhWM2ZRUQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VTVT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE5DdE1oVWZzdVltZFRZRktld0liWlF3Z0hXaXVoX1N1b3VxS09LSTMzMUxHTEJ3VF81b2pjS1FxV2ZSbTlpdGVKcF9qV0hBV2NhZ2lnOHdkbGF6ZGM1TFcySWVLUThZTXlR?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-09T17:38:23+00:00", "published_display": "09 Jul 2025 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vtv Therapeutics (VTVT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBUTkJjeXhQaFN3RVNGV3pMWjFuWEgwUUgwWGFobDluM1YyS2hOMVJ4VnNsLThsNUZTem1DSzQ1dTB3V2VicHhEQjZnWjBmdjRyV2VF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T02:41:16+00:00", "published_display": "25 Apr 2025 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics (VTVT) Stock Forecast and Price Target 2026 $VTVT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE10MV90R19jRGRKSzNCSHhZNmZSekhYT3NYTXo4bUdnN19FMFNUREx2UGg4b2RHelJNc0tlMUNYcGhFVnhrVnQtYkQtUXlDQXI0UzVMMUhPUF9Ha1BnYlBCS0plZ1dOQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-14T23:41:21+00:00", "published_display": "14 May 2024 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTVT: vTv Therapeutics Inc - Ordinary Shares - Class A Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE5DUl9aWWFiOFhlejRjNVFVbmxGZmc2T3dsWmIwRWlxWDhocjhpSWFWZ2VGYzM0czc5azREVDZfZ29BSEdrOS1FREhR?oc=5", "source_name": "Stocktwits", "published_at": "2016-09-29T14:36:42+00:00", "published_display": "29 Sep 2016 14:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "vTv Therapeutics - VTVT - Stock Price Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTFBUald1YVNPSmFJNzNtQmlrVVZvZHFxa3FvU2NEX2liOGFNUGYzOW5oX3dKc0RHUUZ4V3hzNG5PSnF3eXhTQkRmdlIyRWZLeWM?oc=5", "source_name": "Zacks Investment Research", "published_at": "2016-04-28T22:07:54+00:00", "published_display": "28 Apr 2016 22:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 48, "sentiment_summary": {"positive": 11, "negative": 4, "neutral": 33, "score": 53, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 13.7, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 8.46, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 32.88, "latest_week": "2026-07-17", "one_week_move": -1.8, "four_week_move": -6.2, "twelve_week_move": 0.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.738974, "market_dynamics_buy_signal": false, "relative_strength": 0.285104, "fair_value_gap": 54.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 46.5324, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.8% over one week, -6.2% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 9}, {"label": "MarketBeat", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "The Manila Times", "count": 2}, {"label": "dars.gov.et", "count": 1}, {"label": "Simply Wall St.", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.8% over one week, -6.2% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says"}], "updated_at": "2026-07-23T03:57:30.349036+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}